
Results
2
Stocks which the market has priced substantially different to their cash flows, which could imply risk.
2 companies
argenx
Market Cap: €47.8b
A commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
ARGX
€763.80
7D
-8.1%
1Y
59.0%
UCB
Market Cap: €45.1b
A biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide.
UCB
€237.10
7D
-8.6%
1Y
38.7%